

Chemoenzymatic stereoselective synthesis of *trans*-flavan-4-ols via lipase-catalyzed kinetic resolutions

Martín Soto, Irene Sanz-Machín, Humberto Rodríguez-Solla* and
Vicente Gotor-Fernández*

Organic and Inorganic Chemistry Department. University of Oviedo.

Avenida Julián Clavería 8, 33006 Oviedo, Spain. Phone number:

+34985103499 (H.R.-S.); +34985103454 (V.G.-F.); fax number: +34985103446.

E-mail: hrsolla@uniovi.es (H. R.-S.); vicgotfer@uniovi.es (V.G.-F.).

Electronic Supporting Information (Page S1 out of S22)

Index

| | |
|--|-----|
| 1. HPLC conditions | S1 |
| 2. Chromatograms of <i>trans</i> -flavan-4-ols 2a-j in racemic and optically active form | S2 |
| 3. Chromatograms of <i>trans</i> -flavan-4-ol acetates 3a-j in racemic and optically active form | S13 |

1. HPLC conditions


Table S1. HPLC conditions for the chiral analyses of *trans*-flavan-4-ols **2a-j** and their corresponding acetates **3a-j**.^a

| Entry | (±)-Compound | Column | Hexane-2-PrOH (v/v) | Retention times (min) ^b |
|-------|----------------------------------|--------|---------------------|--|
| 1 | <i>trans</i> - 2a (H) | IA | 92:8 | 10.3 (2 <i>S</i> ,4 <i>R</i>) and 10.9 (2<i>R</i>,4<i>S</i>) |
| 2 | <i>trans</i> - 3a (H) | OJ-H | 92:8 | 16.6 (2<i>S</i>,4<i>R</i>) and 28.1 (2 <i>R</i> ,4 <i>S</i>) |
| 3 | <i>trans</i> - 2b (2-F) | OJ-H | 92:8 | 15.3 (2 <i>S</i> ,4 <i>R</i>) and 19.0 (2<i>R</i>,4<i>S</i>) |
| 4 | <i>trans</i> - 3b (2-F) | AS | 92:8 | 5.3 (2 <i>R</i> ,4 <i>S</i>) and 5.6 (2<i>S</i>,4<i>R</i>) |
| 5 | <i>trans</i> - 2c (3-F) | IA | 92:8 | 9.9 (2 <i>S</i> ,4 <i>R</i>) and 10.8 (2<i>R</i>,4<i>S</i>) |
| 6 | <i>trans</i> - 2c (3-F) | OJ-H | 92:8 | 9.9 (2<i>S</i>,4<i>R</i>) and 12.7 (2 <i>R</i> ,4 <i>S</i>) |
| 7 | <i>trans</i> - 2d (4-F) | IA | 92:8 | 10.5 (2 <i>S</i> ,4 <i>R</i>) and 12.3 (2<i>R</i>,4<i>S</i>) |
| 8 | <i>trans</i> - 3d (4-F) | OJ-H | 92:8 | 13.5 (2<i>S</i>,4<i>R</i>) and 16.0 (2 <i>R</i> ,4 <i>S</i>) |
| 9 | <i>trans</i> - 2e (4-Cl) | IA | 92:8 | 11.1 (2 <i>S</i> ,4 <i>R</i>) and 13.1 (2<i>R</i>,4<i>S</i>) |
| 10 | <i>trans</i> - 3e (4-Cl) | AS | 92:8 | 5.7 (2 <i>R</i> ,4 <i>S</i>) and 6.2 (2<i>S</i>,4<i>R</i>) |
| 11 | <i>trans</i> - 2f (4-Br) | IA | 92:8 | 11.6 (2 <i>S</i> ,4 <i>R</i>) and 13.8 (2<i>R</i>,4<i>S</i>) |
| 12 | <i>trans</i> - 3f (4-Br) | OD | 98:2 | 8.8 (2 <i>R</i> ,4 <i>S</i>) and 9.6 (2<i>S</i>,4<i>R</i>) |
| 13 | <i>trans</i> - 2g (2-OMe) | OJ-H | 92:8 | 17.7 (2 <i>S</i> ,4 <i>R</i>) and 20.0 (2<i>R</i>,4<i>S</i>) |
| 14 | <i>trans</i> - 3g (2-OMe) | OJ-H | 92:8 | 13.4 (2 <i>R</i> ,4 <i>S</i>) and 14.6 (2<i>S</i>,4<i>R</i>) |
| 15 | <i>trans</i> - 2h (3-OMe) | OJ-H | 92:8 | 26.0 (2 <i>S</i> ,4 <i>R</i>) and 28.8 (2<i>R</i>,4<i>S</i>) |
| 16 | <i>trans</i> - 3h (3-OMe) | OJ-H | 92:8 | 16.6 (2<i>S</i>,4<i>R</i>) and 23.2 (2 <i>R</i> ,4 <i>S</i>) |
| 17 | <i>trans</i> - 2i (4-OMe) | IA | 92:8 | 15.0 (2 <i>S</i> ,4 <i>R</i>) and 16.6 (2<i>R</i>,4<i>S</i>) |
| 18 | <i>trans</i> - 3i (4-OMe) | IB | 92:8 | 6.5 (2<i>S</i>,4<i>R</i>) and 6.8 (2 <i>R</i> ,4 <i>S</i>) |
| 19 | <i>trans</i> - 2j (4-Me) | IA | 92:8 | 10.4 (2 <i>S</i> ,4 <i>R</i>) and 11.4 (2<i>R</i>,4<i>S</i>) |
| 20 | <i>trans</i> - 3j (4-Me) | OD | 98:2 | 7.1 (2<i>S</i>,4<i>R</i>) and 7.9 (2 <i>R</i> ,4 <i>S</i>) |



^a The temperature column was 30 °C and the flow 0.8 mL/min. Analyses were performed at 210 and 214 nm wavelengths.

^b Major enantiomer of the enzymatic reactions appear in bold font.


2. Chromatograms of *trans*-flavan-4-ols 2a-j in racemic and optically active form




(2R*,4S*)-*trans*-2a





(2R,4S)-*trans*-2a







(2*R,4*S**)-trans-2b**





(2*R*,4*S*)-trans-2b







(2*R,4*S**)-trans-2c**





(2*R*,4*S*)-trans-2c







(2*R,4*S**)-trans-2d**





(2*R*,4*S*)-trans-2d







(2*R,4*S**)-trans-2e**





(2*R*,4*S*)-trans-2e







(2R,4S*)-trans-2f*





(2R,4S)-trans-2f







(2*R,4*S**)-trans-2g**





(2*R*,4*S*)-trans-2g







(2*R,4*S**)-trans-2h**





(2*R*,4*S*)-trans-2h







(2R,4S*)-trans-2i*





(2R,4S)-trans-2i







(2*R,4*S**)-trans-2j**





(2*R*,4*S*)-trans-2j




3. Chromatograms of *trans*-flavan-4-ol acetates 3a-j in racemic and optically active form




(2*S**,4*R**)-*trans*-3a





(2*S*,4*R*)-*trans*-3a







(2*S,4*R**)-trans-3b**





(2*S*,4*R*)-trans-3b







(2*S,4*R**)-trans-3c**





(2*S*,4*R*)-trans-3c







(2*S,4*R**)-trans-3d**





(2*S*,4*R*)-trans-3d







(2*S,4*R**)-trans-3e**





(2*S*,4*R*)-trans-3e







(2*S,4*R**)-trans-3f**





(2*S*,4*R*)-trans-3f







(2*S**,4*R**)-*trans*-3g





(2*S*,4*R*)-*trans*-3g











(2*S,4*R**)-trans-3h**





(2*S*,4*R*)-trans-3h







(2S*,4R*)-trans-3j



(2S,4R)-trans-3j

